Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

pfizer ab - flukonazol - kapsel, hård - 200 mg - flukonazol 200 mg aktiv substans; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne - flukonazol

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

pfizer ab - flukonazol - pulver till oral suspension - 40 mg/ml - natriumbensoat hjälpämne; flukonazol 40 mg aktiv substans; sackaros hjälpämne - flukonazol

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

pfizer ab - flukonazol - kapsel, hård - 50 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; flukonazol 50 mg aktiv substans - flukonazol

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

alfred e tiefenbacher (gmbh & co. kg) - flukonazol - infusionsvätska, lösning - 2 mg/ml - flukonazol 2 mg aktiv substans - flukonazol

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

orifarm ab - flukonazol - pulver till oral suspension - 40 mg/ml - sackaros hjälpämne; natriumbensoat hjälpämne; flukonazol 40 mg aktiv substans

Europese Unie - Zweeds - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastiska medel - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

air liquide santé international - oxygen - medicinsk gas, komprimerad - 100 % - oxygen 100 % aktiv substans - syre

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

pfizer ab - cisplatin - koncentrat till infusionsvätska, lösning - 1 mg/ml - cisplatin 1 mg aktiv substans; mannitol hjälpämne - cisplatin

Europese Unie - Zweeds - EMA (European Medicines Agency)

baxter holding b.v. - doxorubicinhydroklorid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastiska medel - caelyx pegylerat liposomala anges:som monoterapi för patienter med metastaserad bröstcancer, där det finns en ökad risk för hjärt -; för behandling av framskriden äggstockscancer hos kvinnor som har misslyckats med en första linje platinum-baserad kemoterapi behandling, i kombination med bortezomib för behandling av progressiv multipelt myelom hos patienter som har fått minst en tidigare behandling och som redan har genomgått eller är olämpliga för benmärgstransplantation, för behandling av aids-relaterat kaposis sarkom (ks) i patienter med låga cd4 räknas (.

Europese Unie - Zweeds - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicinhydroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiska medel - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).